Ministry of Health to procure innovative cystic fibrosis drug Trikafta

The Ministry of Health will procure the innovative medication Trikafta for patients with cystic fibrosis, following the signing of an agreement with the drug’s manufacturer, US biopharmaceutical company Vertex Pharmaceuticals, according to an announcement by the Ministry of Health.

According to the agency, the medication is authorised by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for patients aged two and over with genetic mutations, matching the approved indications.

“The drug acts directly on the underlying genetic cause of the disease, delivering a marked improvement in lung function indicators and arresting progressive damage. As a result, the risk of infectious complications, the need for hospitalisation, and the necessity of lung transplantation are substantially reduced. The medication significantly improves nutritional status and quality of life, enabling patients to lead longer, fuller, and more active lives. Cystic fibrosis is a progressive genetic condition that typically manifests in childhood, primarily affecting the lungs and digestive system. Respiratory infections are frequent, and over time, pulmonary function and overall health deteriorate significantly. The need for continuous treatment and the limitations imposed by the illness place a considerable burden on children’s daily lives and development; consequently, access to modern therapy is of paramount importance. In September 2025, Trikafta was added to the World Health Organisation’s Model List of Essential Medicines, confirming its critical role in contemporary cystic fibrosis treatment,” the official statement reads.